RA
ABOS icon

Rise Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Rise Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-373
Closed -$410 – 1540
2025
Q1 		$410 Buy
+373
New +$533 ﹤0.01% 1402

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Rise Advisors's ABOS Position: Q2 2025 in Review

Rise Advisors sold out of Acumen Pharmaceuticals (ABOS) in Q2 2025, closing a stake of 373 shares — an estimated $410 sold.

Rise Advisors first reported a position in ABOS in Q1 2025 and held it in 1 quarter. The position peaked at $410 in Q1 2025. 71 funds tracked by Wall St. Rank hold ABOS as of Q2 2025.

  • Rise Advisors reported no remaining Acumen Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Rise Advisors sold 373 Acumen Pharmaceuticals shares in Q2 2025, an estimated $410.
  • Rise Advisors first reported a position in Acumen Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Rise Advisors's Acumen Pharmaceuticals position peaked at $410 in Q1 2025.
  • 71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2025.

Based on Rise Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.